Dawn Bell, PharmD
Global Development Head, Strategic Partnerships
Dawn Bell, Pharm.D. is a global biopharma executive and board director with 20+ years of proven success starting and scaling life-sciences businesses from academic spinouts to Top 5 Pharma. She’s led development and launch of a dozen medicines including Entresto ($3.5B) for heart failure, obtaining Fast Track and Break Through status from the FDA. Her diverse experience across the value chain includes buy and sell-side BD&L, portfolio strategy, clinical development, and commercialization. At Novartis, Dawn has held leadership roles across strategy, medical affairs, business development, and global drug development. She is a start-up thought leader, board director and advisor for privately held life-science companies, research institutes, CEOs, founders, and innovation accelerators in the US and Europe. She was selected by founders as Mentor of the Year for the Creative Destruction Lab in Toronto. As Executive Council Member at EIT Health’s Gold Track, she helped ventures raise €500M, secure 24 partnerships and achieve three exits totaling over €1B in four years.